Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

AERIE PHARMACEUTIC Form 4 March 17, 2014	ALS INC							
) STATES	ES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						PPROVAL 3235-0287
Section 16. Form 4 or Form 5 Filed p	ursuant to S 7(a) of the l	F CHAN Section	NGES IN SECUF 16(a) of th Jtility Hol	BENEF RITIES e Securit ding Con	ICIAL OV	WNERSHIP OF nge Act of 1934, of 1935 or Section 940	Expires: Estimated a burden hou response	irs per
(Print or Type Responses)								
1. Name and Address of Reportin MITRO THOMAS A	g Person <u>*</u>	Symbol			Trading	5. Relationship o Issuer C (Che	of Reporting Per eck all applicable	
(Last) (First) C/O AERIE PHARMACEUTICALS, IN U.S. HIGHWAY 206, SUI			of Earliest Ti Day/Year) 2014	ransaction		Director X Officer (giv below) Pre		6 Owner er (specify
(Street)			endment, Da onth/Day/Yea	-	1	6. Individual or . Applicable Line) _X_ Form filed by	One Reporting Po	erson
BEDMINSTER, NJ 07921						Form filed by Person	More than One R	eporting
(City) (State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Report on a separate li	ne for each el	ass of sec	Code V		(D) Price	or indirectly		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of Transactio/Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A) ((D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) <u>(1)</u>	\$ 20.7	03/13/2014		A	126,000		<u>(1)</u>	03/13/2024	Common Stock	126,000

Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
MITRO THOMAS A C/O AERIE PHARMACEUTICALS, INC. 135 U.S. HIGHWAY 206, SUITE 15 BEDMINSTER, NJ 07921			President and COO	
Signatures				
/s/ Richard J. Rubino, Attorney-in-Fact for Th Mitro	nomas A.	03/17	7/2014	
**Signature of Reporting Person		D	ate	
Explanation of Response	e.			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on March 13, 2014 and is scheduled to vest with respect to 25% of the underlying shares on March 13, 2015, and thereafter in 36 equal installments on each monthly anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.